LATS1 and neoplasm: ZFP226 was capable to (1) activate the KIBRA core promoter, a tumor suppressor and upstream regulator of the hippo pathway, resulting in (2) significantly increased KIBRA mRNA as well as protein levels, (3) activation of hippo signaling marked by elevated LATS1 and YAP phosphorylation and (4) reduced viability of breast cancer cells.